VKC
MCID: VRN004
MIFTS: 47

Vernal Keratoconjunctivitis (VKC)

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Vernal Keratoconjunctivitis

MalaCards integrated aliases for Vernal Keratoconjunctivitis:

Name: Vernal Keratoconjunctivitis 20 58
Keratoconjunctivitis, Vernal 70
Keratoconjunctivitis Vernal 54
Spring Catarrh 58
Vkc 20

Characteristics:

Orphanet epidemiological data:

58
vernal keratoconjunctivitis
Inheritance: Not applicable; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
Orphanet: 58  
Rare eye diseases


External Ids:

ICD10 via Orphanet 33 H16.2
UMLS via Orphanet 71 C0022577
Orphanet 58 ORPHA70476
UMLS 70 C0022577

Summaries for Vernal Keratoconjunctivitis

GARD : 20 Vernal keratoconjunctivitis (VKC) is a chronic, severe allergy that affects the surfaces of the eyes. It most commonly occurs in boys living in warm, dry climates. Attacks associated with VKC are common in the spring (hence the name "vernal") and summer but often reoccur in the winter. Signs and symptoms usually begin before 10 years of age and may include hard, cobblestone-like bumps (papillae) on the upper eyelid; sensitivity to light; redness; sticky mucus discharge; and involuntary blinking or spasms of the eyelid (blepharospasm). The condition usually subsides at the onset of puberty. It is caused by a hypersensitivity (allergic reaction) to airborne-allergens. Management focuses on preventing "flare ups" and relieving the symptoms of the condition.

MalaCards based summary : Vernal Keratoconjunctivitis, also known as keratoconjunctivitis, vernal, is related to papillary conjunctivitis and vernal conjunctivitis. An important gene associated with Vernal Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and lung, and related phenotypes are photophobia and lacrimation abnormality

Wikipedia : 73 Vernal keratoconjunctivitis (VKC) is a recurrent, bilateral, and self-limiting inflammation of... more...

Related Diseases for Vernal Keratoconjunctivitis

Diseases related to Vernal Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
# Related Disease Score Top Affiliating Genes
1 papillary conjunctivitis 30.6 IL4 CCL24 CCL11
2 vernal conjunctivitis 30.5 RNASE3 IL4 IGHE
3 cytokine deficiency 30.5 IL5 IL13
4 giant papillary conjunctivitis 30.4 RNASE3 IL4 CCL24 CCL11
5 keratoconjunctivitis 30.4 RNASE3 IL5 IL4 IL13 CCL5 CCL24
6 atopic keratoconjunctivitis 30.3 RNASE3 IL5 IL4 IGHE
7 eye disease 29.9 IL5 IL4 IL13 CCL5 CCL11
8 allergic conjunctivitis 29.8 RNASE3 IL5 IL4 IL13 IGHE CCL11
9 conjunctivitis 29.6 RNASE3 IL5 IL4 IL13 IGHE CCL24
10 immune deficiency disease 29.5 IL4 IL13 CCL5 CCL11
11 ige responsiveness, atopic 29.4 RNASE3 IL5 IL4 IL13 IGHE IGES
12 pollen allergy 29.3 RNASE3 IL5 IL13 IGHE
13 conjunctival disease 29.3 RNASE3 IL5 IL4 IL13 CCL5 CCL11
14 chronic conjunctivitis 29.0 RNASE3 IL5 IL4 IL13 IGHE CCL11
15 urticaria 29.0 RNASE3 IL5 IL4 IL13 IGHE
16 proteasome-associated autoinflammatory syndrome 1 28.8 RNASE3 IL5 IL4 IL13 IGHE CCL5
17 rhinitis 28.8 RNASE3 IL5 IL4 IL13 IGHE CCL5
18 dermatitis, atopic 28.4 RNASE3 IL5 IL4 IL13 IGHE IGES
19 allergic asthma 28.3 RNASE3 IL5 IL4 IL13 IGHE CCL5
20 allergic disease 28.3 RNASE3 IL5 IL4 IL13 IGHE IGES
21 dermatitis 28.3 RNASE3 IL5 IL4 IL13 IGHE IGES
22 hypereosinophilic syndrome 28.0 RNASE3 IL5 IL4 IL13 IGHE IGES
23 allergic rhinitis 27.9 RNASE3 IL5 IL4 IL13 IGHE IGES
24 ifap syndrome 2 10.8
25 keratoconus 10.8
26 keratitis, hereditary 10.8
27 steroid-induced glaucoma 10.5
28 limbal stem cell deficiency 10.5
29 astigmatism 10.5
30 keratopathy 10.5
31 yemenite deaf-blind hypopigmentation syndrome 10.4
32 corneal ulcer 10.4
33 intraocular pressure quantitative trait locus 10.4
34 trachoma 10.3
35 loeffler endocarditis 10.3 RNASE3 IL5
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
37 ptosis 10.3
38 hypopyon 10.3
39 chlamydia 10.3
40 irregular astigmatism 10.3
41 corneal ectasia 10.3
42 thyroiditis 10.3
43 ocular hypertension 10.3
44 disseminated eosinophilic collagen disease 10.2 RNASE3 IL5
45 adhesive otitis media 10.2 RNASE3 CCL11
46 eustachian tube disease 10.2 RNASE3 CCL11
47 wells syndrome 10.2 RNASE3 IL5
48 cow milk allergy 10.2 IL5 IL4
49 ocular cicatricial pemphigoid 10.2 RNASE3 IL4
50 strabismus 10.2

Graphical network of the top 20 diseases related to Vernal Keratoconjunctivitis:



Diseases related to Vernal Keratoconjunctivitis

Symptoms & Phenotypes for Vernal Keratoconjunctivitis

Human phenotypes related to Vernal Keratoconjunctivitis:

58 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 photophobia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000613
2 lacrimation abnormality 58 31 hallmark (90%) Very frequent (99-80%) HP:0000632
3 corneal neovascularization 58 31 hallmark (90%) Very frequent (99-80%) HP:0011496
4 pruritus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000989
5 abnormal conjunctiva morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0000502
6 abnormal sclera morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0000591
7 punctate keratitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0011859
8 allergy 58 31 hallmark (90%) Very frequent (99-80%) HP:0012393
9 scarring 58 31 frequent (33%) Frequent (79-30%) HP:0100699
10 abnormal cornea morphology 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Vernal Keratoconjunctivitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.02 CCL11 CCL24 IL13 IL4 IL5

Drugs & Therapeutics for Vernal Keratoconjunctivitis

Drugs for Vernal Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
4
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
5
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
6
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
9
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
10 Immunosuppressive Agents Phase 4
11 Antirheumatic Agents Phase 4
12 Ophthalmic Solutions Phase 4
13 Immunologic Factors Phase 4
14 Cyclosporins Phase 4
15 Antifungal Agents Phase 4
16 Anti-Infective Agents Phase 4
17 Calcineurin Inhibitors Phase 4
18 Dermatologic Agents Phase 4
19 Respiratory System Agents Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Neurotransmitter Agents Phase 4
22 Anti-Allergic Agents Phase 4
23 Neuroprotective Agents Phase 4
24 Protective Agents Phase 4
25 Histamine Antagonists Phase 4
26 Isospaglumic acid Phase 4
27
Histamine Phosphate Phase 4 51-74-1 65513
28 Bronchodilator Agents Phase 4
29 Histamine H1 Antagonists Phase 4
30 Hormones Phase 4
31 Antineoplastic Agents, Hormonal Phase 4
32 Hormone Antagonists Phase 4
33 glucocorticoids Phase 4
34 Anti-Inflammatory Agents Phase 4
35 Anti-Bacterial Agents Phase 4
36 Gastrointestinal Agents Phase 4
37 Antiemetics Phase 4
38
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
39 Pharmaceutical Solutions Phase 3
40 Acidophilus Phase 2, Phase 3
41 Immunoglobulin G Phase 1
42 Immunoglobulins Phase 1
43 Immunoglobulins, Intravenous Phase 1
44 Antibodies Phase 1
45 Antibodies, Monoclonal Phase 1
46
Methylprednisolone hemisuccinate Approved 2921-57-5
47
Methylprednisolone Approved, Vet_approved 83-43-2 6741
48
Prednisolone Approved, Vet_approved 50-24-8 5755
49
Prednisolone acetate Approved, Vet_approved 52-21-1
50
Prednisolone phosphate Approved, Vet_approved 302-25-0

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
3 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
4 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
5 A Double-blind Comparison of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drops in the Treatment of Vernal Keratoconjunctivits (VKC) Completed NCT01068054 Phase 2, Phase 3 tacrolimus;cyclosporins
6 A Randomized, Placebo-controlled, Double-masked Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Vernal Keratoconjunctivitis Completed NCT00567762 Phase 3 FK506;placebo
7 A Multicenter, Randomized, Double-Masked, 3 Parallel Arms, Placebo Controlled Study to Assess the Efficacy and Safety of NOVA22007 1mg/mL (Ciclosporin/Cyclosporine) Eye Drops, Emulsion Administered in Paediatric Patients With Active Severe Vernal Keratoconjunctivitis With Severe Keratitis Completed NCT01751126 Phase 3 NOVA22007 ''Ciclosporin'';Placebo
8 Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Cyclosporine Eye Drop Treatment in Preventing Vernal Keratoconjunctivitis (VKC) Relapses and in Treating the Acute Phase. Completed NCT00426023 Phase 3 Cyclosporine A 0,05% eye drop;ketotifen fumarate 0.025% eye drops
9 Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Lactobacillus Rhamnosus GG Treatment in Preventing Vernal Keratoconjunctivitis VKC) Relapses. Completed NCT00445120 Phase 2, Phase 3 Lactobacillus Rhamnosus GG;placebo (sugar)
10 A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis Completed NCT03379311 Phase 1 AK002
11 Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Steroid Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis Unknown status NCT03557203
12 Cytokine Assay in Tears of Healthy Children and With Vernal Keratocunjonctivitis: Case Control Study and Monitoring of Cases at 6 Months Unknown status NCT02057822
13 Role of Topical Immuonosuppressant in the Management of Spring Catarrh: a Comparative Study Between Cyclosporine A 2% and Tacrolimus 0.3% Not yet recruiting NCT04705584 Prednisolone (as Acetate);CycloSPORINE Ophthalmic Suspension;LTacrolimus Topical

Search NIH Clinical Center for Vernal Keratoconjunctivitis

Genetic Tests for Vernal Keratoconjunctivitis

Anatomical Context for Vernal Keratoconjunctivitis

MalaCards organs/tissues related to Vernal Keratoconjunctivitis:

40
Eye, Skin, Lung, T Cells, Endothelial, Neutrophil, Bone Marrow

Publications for Vernal Keratoconjunctivitis

Articles related to Vernal Keratoconjunctivitis:

(show top 50) (show all 753)
# Title Authors PMID Year
1
Nerve growth factor modulates toll-like receptor (TLR) 4 and 9 expression in cultured primary VKC conjunctival epithelial cells. 61 54
19844589 2009
2
Tearfilm immunoglobulin E (IgE) level in vernal keratoconjunctivitis by ELISA. 61 54
20071840 2009
3
Evaluation of eotaxin-1, -2, and -3 protein production and messenger RNA expression in patients with vernal keratoconjunctivitis. 54 61
19333691 2009
4
Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva. 54 61
17653039 2007
5
Tryptase increases proliferative activity of human conjunctival fibroblasts through protease-activated receptor-2. 54 61
16303958 2005
6
Ocular allergic disease. 54 61
15349048 2004
7
Tear chymase in vernal keratoconjunctivitis. 61 54
15512949 2004
8
The T-lymphocyte chemoattractant Mig is highly expressed in vernal keratoconjunctivitis. 54 61
14597036 2003
9
Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis. 54 61
14501439 2003
10
Synergistic effect of TNF-alpha and either IL-4 or IL-13 on VCAM-1 expression by cultured human corneal fibroblasts. 61 54
12883351 2003
11
Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. 61 54
12824251 2003
12
Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. 61 54
12623809 2003
13
IL-4-induced cell proliferation and production of extracellular matrix proteins in human conjunctival fibroblasts. 54 61
12589780 2003
14
High level of Fc epsilon receptor I-bindable immunoglobulin E in the tear fluid and increased immunoglobulin E-saturated cells in the giant papillae of vernal keratoconjunctivitis patients. 61 54
12225812 2002
15
Nerve growth factor and asthma. 61 54
12144547 2002
16
Expression of chemokine receptors in vernal keratoconjunctivitis. 61 54
11673306 2001
17
Gelatinase B in vernal keratoconjunctivitis. 54 61
11594952 2001
18
Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage. 61 54
11588428 2001
19
Expression of CD23/CD21 and CD40/CD40 ligand in vernal keratoconjunctivitis. 54 61
11339595 2001
20
Chemokines in the limbal form of vernal keratoconjunctivitis. 54 61
11090473 2000
21
Synergistic induction of eotaxin expression in human keratocytes by TNF-alpha and IL-4 or IL-13. 61 54
10798661 2000
22
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 61 54
10682966 2000
23
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 61 54
10606937 2000
24
Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. 61 54
10469030 1999
25
Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. 61 54
10224366 1999
26
Increased plasma levels of substance P in vernal keratoconjunctivitis. 54 61
9331280 1997
27
ICAM-1 expression in corneal epithelium of a patient with vernal keratoconjunctivitis: case report. 54 61
8985642 1997
28
Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. 54 61
9135403 1997
29
Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis. 54 61
7586697 1995
30
Increased plasma levels of nerve growth factor in vernal keratoconjunctivitis and relationship to conjunctival mast cells. 54 61
7657550 1995
31
Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. 54 61
8588697 1995
32
IgE, IgE receptors, and other immunocytochemical markers in atopic and nonatopic patients with vernal keratoconjunctivitis. 61 54
7777271 1995
33
Vernal keratoconjunctivitis: a model of 5q cytokine gene cluster disease. 61 54
7613225 1995
34
Collagen types I and III in giant papillae of vernal keratoconjunctivitis. 61 54
7612563 1995
35
Increased serum levels of eosinophil cationic protein and eosinophil-derived neurotoxin (protein X) in vernal keratoconjunctivitis. 61 54
7800361 1994
36
Conjunctival Inclusion Cysts in Chronic Vernal Keratoconjunctivitis: String of Pearls. 61
33745524 2021
37
Comparative profile of ocular surface microbiome in vernal keratoconjunctivitis patients and healthy subjects. 61
33651203 2021
38
Corneal and lens densitometry with Pentacam HR in children with vernal keratoconjunctivitis. 61
32945010 2021
39
Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus. 61
33764241 2021
40
Clinical efficacy and safety of omalizumab in conventional treatment-resistant vernal keratoconjunctivitis: Our experience and literature review. 61
33434384 2021
41
Systemic diseases and the cornea. 61
33485845 2021
42
Comparative efficacy of medical treatments for vernal keratoconjunctivitis in children and young adults: a systematic review with network meta-analyses. 61
33779061 2021
43
Role of combined immunomodulator therapy in severe steroid intolerant vernal keratoconjunctivitis. 61
32518397 2021
44
Corneal and lens densitometry in patients with vernal keratoconjunctivitis. 61
33754236 2021
45
Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases. 61
33522964 2021
46
Current Knowledge in Allergic Conjunctivitis. 61
33631915 2021
47
A polymeric aqueous tacrolimus formulation for topical ocular delivery. 61
33571621 2021
48
Role of oncostatin M in the pathogenesis of vernal keratoconjunctivitis: focus on tissue remodeling. 61
33403505 2021
49
Ocular surface disease associated with dupilumab treatment for atopic diseases. 61
32439390 2021
50
Anterior segment optical coherence tomography features of pseudoepitheliomatous hyperplasia of the ocular surface: a study of 9 lesions. 61
32839863 2021

Variations for Vernal Keratoconjunctivitis

Expression for Vernal Keratoconjunctivitis

Search GEO for disease gene expression data for Vernal Keratoconjunctivitis.

Pathways for Vernal Keratoconjunctivitis

Pathways related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 RNASE3 IL5 IL4 IL13 IGHE CCL5
2
Show member pathways
13.55 IL5 IL4 IL13 CCL5 CCL24 CCL11
3
Show member pathways
13.41 IL5 IL4 IL13 CCL5 CCL24 CCL11
4
Show member pathways
13.3 IL5 IL4 IL13 CCL5 CCL24 CCL11
5
Show member pathways
13.17 IL5 IL4 IL13 CCL5 CCL24 CCL11
6
Show member pathways
13.12 IL5 IL4 IL13 IGHE CCL5 CCL11
7
Show member pathways
13.07 IL5 IL4 IL13 CCL5 CCL24 CCL11
8
Show member pathways
12.62 RNASE3 IL5 IL4 IL13 CCL11
9
Show member pathways
12.41 IL5 IL4 IL13 IGHE
10
Show member pathways
12.21 IL5 IL4 IL13
11
Show member pathways
12.19 IL4 IGHE CCL11
12
Show member pathways
12.15 IL5 IL4 IL13 CCL11
13
Show member pathways
12.14 CCL5 CCL24 CCL11
14
Show member pathways
12.12 CCL5 CCL24 CCL11
15 11.73 IL4 IL13 IGHE CCL11
16 11.66 IL5 IL4 IL13
17 11.64 IL5 IL4 IL13
18 11.36 IL4 IL13 CCL5
19 11.26 IL5 IL4 IGHE CCL11
20 11.14 IL5 IL4
21 11.14 IL5 IL4 IL13
22 11.07 IL5 IL4 IL13
23 11 IL5 IL4 IL13
24 10.92 IL5 IL4 IL13 CCL11
25 10.82 IL5 IL4 IL13 CCL5 CCL11
26 10.64 IL5 IL4 IL13 CCL5 CCL24 CCL11
27 10.58 IL5 IL4 IL13

GO Terms for Vernal Keratoconjunctivitis

Cellular components related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 RNASE3 IL5 IL4 IL13 CCL5 CCL24
2 extracellular region GO:0005576 9.23 RNASE3 IL5 IL4 IL13 IGHE CCL5

Biological processes related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.78 CCL5 CCL24 CCL11
2 positive regulation of cell migration GO:0030335 9.78 IL4 CCL5 CCL24 CCL11
3 cellular response to tumor necrosis factor GO:0071356 9.75 CCL5 CCL24 CCL11
4 cellular response to interferon-gamma GO:0071346 9.72 CCL5 CCL24 CCL11
5 cellular response to interleukin-1 GO:0071347 9.71 CCL5 CCL24 CCL11
6 neutrophil chemotaxis GO:0030593 9.7 CCL5 CCL24 CCL11
7 chemokine-mediated signaling pathway GO:0070098 9.69 CCL5 CCL24 CCL11
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IL4 IL13 CCL5
9 inflammatory response GO:0006954 9.65 IL5 IL13 CCL5 CCL24 CCL11
10 positive regulation of interleukin-10 production GO:0032733 9.62 IL4 IL13
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 IL4 IL13
12 chemotaxis GO:0006935 9.62 RNASE3 CCL5 CCL24 CCL11
13 positive regulation of JAK-STAT cascade GO:0046427 9.61 IL5 CCL5
14 monocyte chemotaxis GO:0002548 9.61 CCL5 CCL24 CCL11
15 microglial cell activation GO:0001774 9.6 IL4 IL13
16 innate immune response in mucosa GO:0002227 9.59 RNASE3 IL4
17 positive regulation of immunoglobulin production GO:0002639 9.58 IL5 IL13
18 positive regulation of B cell proliferation GO:0030890 9.58 IL5 IL4 IL13
19 macrophage activation GO:0042116 9.57 IL4 IL13
20 positive regulation of mast cell degranulation GO:0043306 9.56 IL4 IL13
21 lymphocyte chemotaxis GO:0048247 9.54 CCL5 CCL24 CCL11
22 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
23 cytokine-mediated signaling pathway GO:0019221 9.43 IL5 IL4 IL13 IGHE CCL5 CCL11
24 eosinophil chemotaxis GO:0048245 9.33 CCL5 CCL24 CCL11
25 immune response GO:0006955 9.17 IL5 IL4 IL13 IGHE CCL5 CCL24

Molecular functions related to Vernal Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor ligand activity GO:0048018 9.37 CCL24 CCL11
2 chemokine activity GO:0008009 9.33 CCL5 CCL24 CCL11
3 cytokine receptor binding GO:0005126 9.32 IL4 IL13
4 CCR3 chemokine receptor binding GO:0031728 9.26 CCL24 CCL11
5 CCR chemokine receptor binding GO:0048020 9.13 CCL5 CCL24 CCL11
6 cytokine activity GO:0005125 9.1 IL5 IL4 IL13 CCL5 CCL24 CCL11

Sources for Vernal Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....